Importantly, several inhibitors of the USP1/UAF1 complex have been recently shown to act synergistically with cisplatin in cancer-derived cell lines [1,14,15], suggesting that this complex may represent a valid therapeutic target in cancer. This evidence concerns the gene WDR48 and cancer.